[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:dmpk-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"DMPK Gene",8,7,[8,16,23,30,36,42,48,54],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05004129","Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy",[12],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:18:26.932189Z","2026-05-05T02:43:28.630008Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07486934","Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1",[20],"Phase 3","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.134269Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06300307","Study of ATX-01 in Participants With DM1",[27],"Phase 1\u002FPhase 2","2026-08-26T02:17:35.666428Z","2026-05-05T02:43:27.264646Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT05481879","Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1",[27],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:26.746706Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07700225","Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension",[],"2026-08-26T02:17:29.353236Z","2026-07-19T19:36:05.081727Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06747884","Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension",[],"2026-08-26T02:17:21.315591Z","2026-05-13T02:55:06.569377Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05224778","DMCRN-02-001: Assessing Pediatric Endpoints in DM1",[],"2026-08-26T02:18:51.833592Z","2026-05-13T02:55:06.295515Z",{"nct_id":55,"title":56,"phases":57,"status":58,"updated_at":59,"content_modified":60},"NCT07008469","Global Open-Label Extension Study of Del-desiran for the Treatment of DM1",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:15:58.452248Z","2026-06-16T05:54:07.849416Z"]